1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Exelixis' CELESTIAL Liver Trial Succeeds, But Can Cabozantinib Compete?

 
• By Emily Hayes

CELESTIAL second-line liver cancer study is positive, but 4% response rate pales in comparison to PD-1 performance of Bristol's Opdivo and Merck's Keytruda.

Liver cancer, CT scan upper abdomen.

Exelixis Inc.'s data for its tyrosine kinase inhibitor cabozantinib in the Phase III CELESTIAL study of second-line-plus advanced hepatocellular cancer are positive, but raised some concerns about competitive prospects, particularly against Bristol-Myers Squibb Co.'s approved PD-1 inhibitor Opdivo and Merck & Co. Inc.'s Keytruda, which is also now poised for approval in this tumor type.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten

 
• By Alaric DeArment

BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.

Disappointing Asthma Phase II Results Take Wind Out Of Sanofi’s Amlitelimab

 
• By Andrew McConaghie

Sanofi’s OX40L candidate missed a Phase II primary endpoint, but the company believes it can still work in a sub-group of ‘heterogeneous inflammatory asthma’ patients.

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

 
• By Andy Smith

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

More from R&D

Ironwood To Consider All Options With Apraglutide Setback In SBS

 
• By Joseph Haas

With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

Amgen’s Imdelltra Sets The Pace In Small-Cell Lung Cancer

 
• By Andrew McConaghie

The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.